greeksoup/ stock research

OptimizeRx Corp.: Q2 FY2026 earnings call

What management said about Q2 FY2026, from the documents filed with the SEC on 12 August 2026: press release. Guidance figures: 2 kept. The quarter’s numbers.

Key takeaways

  • Revenue fell 30% year over year: Q2 2026 revenue was $20.5 million, against $29.2 million a year earlier and $19.8 million in Q1 2026. Six-month revenue was $40.3 million versus $51.1 million. Source
  • Net loss against prior-year profit: GAAP net loss was $(0.7) million, or $(0.04) per share, against net income of $1.5 million in Q2 2025. Non-GAAP net income was $3.1 million, or $0.16 per diluted share, versus $3.7 million. Source
  • Adjusted EBITDA of $4.9 million: Adjusted EBITDA was $4.9 million, against $5.8 million in Q2 2025 and $3.3 million in Q1 2026. Source
  • Full-year guidance reaffirmed: Management reaffirmed FY2026 revenue of $95 million to $100 million and adjusted EBITDA of $21 million to $25 million. Source
  • EHR network integrated with DSP: DeepIntent, a demand-side platform, became the first healthcare DSP to integrate the company's authenticated EHR network during the quarter. Source
  • Declines concentrated in few customers: Management said the year-over-year revenue decline and below-prior-year contracted revenue are concentrated among a small number of customers. Source
  • Second-half timing and mix vary: Management cited some variability in second-half timing and mix, and pointed to first-half performance and commercial momentum in reiterating guidance. Source
  • Term loan paid ahead of schedule: Management said $5.3 million of term loan principal was repaid in the quarter, $5.0 million ahead of schedule, with a further $3.0 million after quarter-end. Total repayment since inception is $8.3 million. Source

“Second quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and resilience in our operating model.”

Stephen L. Silvestro, OptimizeRx CEO

Guidance

AreaPeriodFigureAgainst last quarter
Revenue Sourcefiscal year 2026$95 million to $100 millionKept
Adjusted EBITDA Sourcefiscal year 2026$21 million to $25 millionKept

What changed from last quarter

  • Guidance kept: FY2026 revenue of $95 million to $100 million and adjusted EBITDA of $21 million to $25 million were reiterated, matching the guidance in the first-quarter release. Source
  • New: DeepIntent became the first healthcare demand-side platform to integrate the company's authenticated electronic health record network. Source
  • New: A patent-pending Natural Language Audience Builder was launched during the quarter. Source
  • New: CopayCue, described as a next-generation copay activation solution, was introduced. Source

Results and full-year guidance

  • Revenue fell 30% year over year: Q2 2026 revenue was $20.5 million, against $29.2 million a year earlier and $19.8 million in Q1 2026. Six-month revenue was $40.3 million versus $51.1 million. Source
  • Net loss against prior-year profit: GAAP net loss was $(0.7) million, or $(0.04) per share, against net income of $1.5 million in Q2 2025. Non-GAAP net income was $3.1 million, or $0.16 per diluted share, versus $3.7 million. Source
  • Adjusted EBITDA of $4.9 million: Adjusted EBITDA was $4.9 million, against $5.8 million in Q2 2025 and $3.3 million in Q1 2026. Source
  • Operating income turned to loss: Loss from operations was $(88) thousand, against income of $3,207 thousand in Q2 2025. Six-month income from operations was $308 thousand versus $1,105 thousand. Source
  • Full-year guidance reaffirmed: Management reaffirmed FY2026 revenue of $95 million to $100 million and adjusted EBITDA of $21 million to $25 million. Source

Customers and key performance indicators

  • Top 20 manufacturers' revenue share fell: Revenue from the top 20 pharmaceutical manufacturers was 54% of total on a rolling twelve-month basis to June 30, 2026, against 59% a year earlier. Source
  • Net revenue retention dropped to 90%: Rolling twelve-month net revenue retention was 90%, against 121% a year earlier. The first-quarter release reported 110% for the period to March 31, 2026. Source
  • Average revenue per top 20 fell: Average revenue per top 20 pharmaceutical manufacturer was $2,659 thousand on a rolling twelve-month basis, against $3,095 thousand a year earlier. Source
  • Top 20 list updated, prior periods restated: The top 20 pharmaceutical manufacturers definition now follows Fierce Pharma's list by 2025 revenue. Prior periods have been restated for comparison. Source
  • Revenue per employee slightly lower: Revenue per average full-time employee was $750 thousand on a rolling twelve-month basis, against $767 thousand a year earlier. Source

“While year-over-year revenue declined and contracted revenue remains below prior-year levels, these trends are concentrated among a small number of customers”

Stephen L. Silvestro, OptimizeRx CEO

Platform and product launches

  • EHR network integrated with DSP: DeepIntent, a demand-side platform, became the first healthcare DSP to integrate the company's authenticated EHR network during the quarter. Source
  • Patent-pending audience builder launched: The Natural Language Audience Builder, which is patent-pending, was launched in the quarter. Source
  • CopayCue copay activation introduced: CopayCue was introduced as a next-generation copay activation solution. Source
  • Launches aimed at AI audiences: Management said the three platform advancements strengthen AI-enabled audience intelligence, programmatic point-of-care activation and clinical workflow engagement. Source

Costs and non-GAAP items

  • Cost of revenues fell about 54%: Cost of revenues was $4.8 million in Q2 2026, compared with $10.6 million in Q2 2025 and $4.9 million in Q1 2026. Source
  • Operating expenses little changed: Sales and marketing was $5.5 million against $5.9 million, G&A $3.7 million against $3.9 million, and R&D $3.3 million against $3.1 million. Source
  • Severance excluded from non-GAAP: Severance of $1.7 million in Q2 2026 was added back in non-GAAP results. Stock-based compensation was $2.2 million against $1.5 million. Source

“Despite some variability in second-half timing and mix, our first-half performance and commercial momentum give us confidence to reiterate full-year 2026 guidance”

Stephen L. Silvestro, OptimizeRx CEO

Demand and customer concentration

  • Declines concentrated in few customers: Management said the year-over-year revenue decline and below-prior-year contracted revenue are concentrated among a small number of customers. Source
  • Investment rising across other customers: Management said it is encouraged by increased investment across other parts of its customer base. Source
  • Second-half timing and mix vary: Management cited some variability in second-half timing and mix, and pointed to first-half performance and commercial momentum in reiterating guidance. Source

Capital, debt and cash

  • Term loan paid ahead of schedule: Management said $5.3 million of term loan principal was repaid in the quarter, $5.0 million ahead of schedule, with a further $3.0 million after quarter-end. Total repayment since inception is $8.3 million. Source
  • Refinanced with $35 million facility: The refinancing comprises a $25 million term loan and a $10 million revolver, which was undrawn at quarter-end, within a $35 million traditional banking facility. Source
  • Cash rose to $24.1 million: Cash and cash equivalents were $24.1 million at June 30, 2026, against $23.4 million at December 31, 2025. Six-month operating cash flow was $8.1 million, against $8.4 million. Source
  • Receivables fell from year-end: Accounts receivable were $24.8 million at June 30, 2026, against $37.8 million at December 31, 2025. Source

Coming up, as management said on 12 August 2026

  • Customer investment into 2027 planning: Management said continued platform investment and programmatic initiatives are strengthening customer engagement as it moves into the 2027 planning cycle. Source

In management's words

“paying down $5.3 million of term loan principal during the quarter - $5.0 million ahead of schedule - and an additional $3.0 million subsequent to quarter-end”

Stephen L. Silvestro, OptimizeRx CEO

Figures management reported

FigureReported
Average revenue per top 20 pharmaceutical manufacturers Source$2,659 thousand (rolling twelve months to June 30, 2026; $3,095 thousand prior year)
Percent of total revenue from top 20 pharmaceutical manufacturers Source54% (prior year 59%)
Net revenue retention Source90% (prior year 121%)
Revenue per average full-time employee Source$750 thousand (prior year $767 thousand)

Risks management discussed

  • Demand: Management described revenue decline as concentrated among a small number of customers, with contracted revenue still below prior-year levels. Source
  • Demand: Management cited some variability in second-half timing and mix as a factor in the second half of the year. Source

Earlier plans management reported on

  • Not stated: Management said first-half performance and commercial momentum support reiterating FY2026 revenue of $95 million to $100 million and adjusted EBITDA of $21 million to $25 million. Source
  • Ahead: Management said $5.0 million of the $5.3 million repaid in the quarter was ahead of schedule. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.